Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain

Tapentadol for pain: a treatment evaluation

“…A cost-effectiveness analysis has been performed examining the use of tapentadol IR in acute pain [16]. These authors found that the increased drug costs were offset by reductions in expenses due to the treatment of adverse events and the costs associated with treatment discontinuation with conversion to alternative opioid analgesics.…”

Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients

“…These studies concluded that tapentadol is cost effective compared with oxycodone alone [118][119][120][121][122] or in combination with naloxone [123], but not with morphine or transdermal fentanyl [119]. However, these data should be treated with caution as they all come from studies carried out directly [118][119][120][121][122] or indirectly [123] by companies marketing tapentadol. Methodological limitations also make their interpretation difficult, such as the lack of direct comparison between tapentadol and its comparator, or the diversity of models used from one study to another [124,125].…”

Tapentadol for Multimodal Pain Management

“…10 Tapentadol 50 to 75 mg has been shown to produce comparable analgesia and significantly better gastrointestinal (GI) tolerability compared with 10 mg of short-acting oxycodone, 11 and it has been described as a cost-effective alternative to oxycodone. 12 Its unique dual mechanism of action gives tapentadol a built-in advantage over other analgesics as an option for clinicians who want to apply the currently recommended multimodal analgesia approach to pain treatment. [13][14][15] A randomized controlled trial of 901 patients after bunionectomy found that 50-or 75-mg doses of tapentadol produced similar pain relief as 10 mg of oxycodone every 4 to 6 hours with a better adverse effect profile, particularly GI adverse effects with 50 mg of tapentadol.…”